CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+22.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$295M
AUM Growth
+$295M
(+19%)
Cap. Flow
+$10.2M
Cap. Flow
% of AUM
3.44%
Top 10 Holdings %
Top 10 Hldgs %
32.39%
Holding
456
New
65
Increased
317
Reduced
38
Closed
9
Top Buys
| 1 |
NVIDIA
NVDA
|
$7.81M |
| 2 |
PayPal
PYPL
|
$4.77M |
| 3 |
STAAR Surgical
STAA
|
$3.64M |
| 4 |
Chipotle Mexican Grill
CMG
|
$3.46M |
| 5 |
Microsoft
MSFT
|
$3.33M |
Top Sells
| 1 |
iQIYI
IQ
|
$7.64M |
| 2 |
Pinduoduo
PDD
|
$6.59M |
| 3 |
ON Semiconductor
ON
|
$4.45M |
| 4 |
Apple
AAPL
|
$3.07M |
| 5 |
Rambus
RMBS
|
$2.77M |
Sector Composition
| 1 | Technology | 38.43% |
| 2 | Consumer Discretionary | 23.55% |
| 3 | Healthcare | 18.31% |
| 4 | Communication Services | 8.83% |
| 5 | Financials | 4.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
326
Amarin Corp
AMRN
$311M
| $7.76K | ﹤0.01% |
5,174
+1,096
| +27% | +$1.64K |
|
327
Fate Therapeutics
FATE
$119M
| $7.58K | ﹤0.01% |
1,330
+343
| +35% | +$1.96K |
|
328
Diamondback Energy
FANG
$43.4B
| $7.57K | ﹤0.01% |
+56
| New | +$7.57K |
|
329
4D Molecular Therapeutics
FDMT
$287M
| $7.55K | ﹤0.01% |
439
+110
| +33% | +$1.89K |
|
|
ICPT
330
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.53K | ﹤0.01% |
561
+140
| +33% | +$1.88K |
|
331
HilleVax
HLVX
$105M
| $7.47K | ﹤0.01% |
452
+113
| +33% | +$1.87K |
|
|
BCYC
332
Bicycle Therapeutics
BCYC
$511M
| $7.42K | ﹤0.01% |
349
+90
| +35% | +$1.91K |
|
333
Aclaris Therapeutics
ACRS
$216M
| $7.31K | ﹤0.01% |
903
+225
| +33% | +$1.82K |
|
334
Coherus Oncology, Inc. Common Stock
CHRS
$138M
| $7.21K | ﹤0.01% |
1,054
+264
| +33% | +$1.81K |
|
335
eBay
EBAY
$41.1B
| $7.19K | ﹤0.01% |
+162
| New | +$7.19K |
|
336
Galapagos
GLPG
$2.05B
| $7.03K | ﹤0.01% |
182
+46
| +34% | +$1.78K |
|
337
Alector
ALEC
$262M
| $6.96K | ﹤0.01% |
1,125
+285
| +34% | +$1.76K |
|
338
MaxCyte
MXCT
$143M
| $6.84K | ﹤0.01% |
1,382
+345
| +33% | +$1.71K |
|
339
Editas Medicine
EDIT
$222M
| $6.78K | ﹤0.01% |
935
+237
| +34% | +$1.72K |
|
|
ITOS
340
DELISTED
iTeos Therapeutics
ITOS
| $6.56K | ﹤0.01% |
482
+121
| +34% | +$1.65K |
|
341
Evolus
EOLS
$485M
| $6.45K | ﹤0.01% |
762
+191
| +33% | +$1.62K |
|
342
Arbutus Biopharma
ABUS
$732M
| $6.42K | ﹤0.01% |
2,120
+530
| +33% | +$1.61K |
|
|
NSTG
343
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.28K | ﹤0.01% |
634
+160
| +34% | +$1.58K |
|
344
Lexicon Pharmaceuticals
LXRX
$407M
| $6.21K | ﹤0.01% |
2,557
+639
| +33% | +$1.55K |
|
345
Mersana Therapeutics
MRSN
$36.5M
| $6.01K | ﹤0.01% |
1,463
+449
| +44% | +$1.85K |
|
346
Karyopharm Therapeutics
KPTI
$58.8M
| $5.98K | ﹤0.01% |
1,536
+711
| +86% | +$2.77K |
|
347
MacroGenics
MGNX
$110M
| $5.97K | ﹤0.01% |
833
+209
| +33% | +$1.5K |
|
348
Procter & Gamble
PG
$368B
| $5.95K | ﹤0.01% |
40
| – | – |
|
349
HUTCHMED
HCM
$2.58B
| $5.92K | ﹤0.01% |
455
+80
| +21% | +$1.04K |
|
350
Wave Life Sciences
WVE
$1.53B
| $5.74K | ﹤0.01% |
1,325
+442
| +50% | +$1.91K |
|